Browse press releases
The newest releases come first, each with its full text here and a link to its original. Try the filters to narrow them down.
- OMP and PwC Alliance Moves Process Manufacturers from Siloed Supply Chain Planning to Unified DecisionsANTWERPEN, BELGIUM, Sept 23, 2026 - OMP and PwC have formed an alliance to bring unified, faster supply chain decisions to process manufacturers in life sciences, consumer goods, and chemicals. Planning in these industries runs on campaign production, long lead times, and regulatory requirements, all surfacing "too late to act on" when planning sits in separate systems. The alliance combines Unison Planning™, OMP's AI-enabled planning platform with built-in industry expertise, and PwC's implementation services. German specialty pharmaceutical company medac is already live under the alliance, with its planners working on a single demand plan in Unison Planning™. PwC and medac will present the project on October 15, 2026, at the OMP Conference in Singapore, detailing the approach behind the rollout and what it means for planning in pharma. Combining innovation, industry knowledge, and integration OMP and PwC run each implementation as a single program. OMP brings Unison Planning™, its AI-enabled platform with built-in industry expertise, connecting to the systems that a manufacturer already runs. PwC's teams lead the implementation, acting as system integrator and working directly alongside the customer's own planners. Both organizations see the same shift across life sciences, consumer goods, and chemicals: manufacturers replacing fragmented planning with a unified end-to-end plan, and looking for a platform and an implementation team that already know their industry. "Process manufacturers face the same planning constraints, whatever their size, and few have spare program capacity to absorb an implementation. That is where the combination of the platform, the industry knowledge, and an integrator who can run the program matters most," said Dieter Sleeuwaert, Senior Vice President Global Alliances at OMP. medac moves from spreadsheets to a single demand plan medac supplies specialty treatments in rheumatology, urology, hematology, and oncology to more than 90 countries, manufacturing at its own European sites. Its planning ran on a mix of spreadsheets, planning functions within its existing ERP system, and a separate tool with limited planning capability. Processes also differed by department and by geography. PwC, medac and OMP started with a focused demand planning release, resulting in an accelerated go-live for German planners ahead of the wider rollout. The remaining geographies, a supply planning layer, and a second release running in parallel with medac's SAP S/4 implementation will follow. "Leading with the demand planning release and holding the solution close to standard is what made it work. That approach transfers to other companies in the sector," said Jörg Zietz, Director, Supply Chain Planning at PwC Germany. PwC and medac on stage in Singapore Dr. Karsten Gentner, Vice President Supply Chain Management and Procurement at medac, and Jörg Zietz of PwC Germany will explain how medac is building the digital backbone for a smarter, more resilient, and AI-ready pharmaceutical supply chain. Their session takes place on October 15, 2026 at the OMP Conference in Singapore. Register for the event. About PwC At PwC, we help clients build trust and reinvent so they can turn complexity into a competitive advantage. We're a tech-forward, people-empowered network with more than 364,000 people in 136 countries and 137 territories. Across audit and assurance, tax and legal, deals and consulting, we help clients build, accelerate, and sustain momentum. About medac The medac Group is committed to improving patients' quality of life worldwide by providing access to the best possible medical therapies. As a globally operating pharmaceutical company headquartered in Germany, we are active in more than 90 countries and employ over 2,000 people worldwide. With production sites in Europe and a focus on rheumatology, urology, hematology, and oncology, medac develops and markets high-quality originator products, generics, and biosimilars. About OMP OMP helps companies facing complex planning challenges to excel, grow, and thrive by offering the best digitized supply chain planning solution on the market. Hundreds of customers in a wide range of industries - spanning consumer goods, life sciences, chemicals, metals, paper, packaging, plastics, tires, and building products - benefit from using OMP's unique Unison Planning™. Solution and product inquiries Contact OMP +32 3 650 22 11 Media inquiries Kira Perdue (Carabiner) SOURCE: OMP
- ViferaXS GmbHViferaXS Raises €12 Million to Advance Phase II Trial in Chronic Lymphocytic Leukemia and Expand Its Oncology PipelineFinancing round of €12 million closed, including grant funding, led by SPRIND (the German Federal Agency for Breakthrough Innovation) and Huma, with participation from private investors Proceeds fund a Phase II trial of CLLTAXS01 in chronic lymphocytic leukemia (CLL), plus upcoming Phase...
- MaxCyte, IncMaxCyte Appoints Sidharth Kapileshwar as Chief Corporate Development OfficerMaxCyte, Inc. (Nasdaq: MXCT), a leading cell engineering company providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell therapeutics, today announced that it has appointed Sidharth Kapileshwar as Chief Corporate Development Officer.
- Annovis Announces Partnership with Weave Bio, AI Regulatory Platform, in Preparation of NDA for Buntanetap in Alzheimer’s DiseaseAnnovis Bio, Inc. (NYSE: ANVS) (“Annovis” or the “Company”), a Phase 3 clinical-stage biotechnology company developing the investigational oral therapy, buntanetap, for neurodegenerative diseases such as Alzheimer’s disease (AD) and Parkinson’s disease (PD), today announced a collaboration with Weave Bio, an AI platform for regulatory content and knowledge management, in support of the planned New Drug Application (NDA) for buntanetap.
- Altimmune, IncAltimmune to Participate in Stifel Cardiometabolic ForumAltimmune, Inc. (Nasdaq: ALT), a late clinical-stage biopharmaceutical company developing pemvidutide to address serious liver diseases, today announced that management will participate in a fireside chat at the Stifel 2026 Virtual Cardiometabolic Forum on Wednesday, September 30, 2026, at 10:30 a.m. ET.
- MeiraGTx LONDON andMeiraGTx Appoints Accomplished Healthcare Portfolio Manager Alan M. Sebulsky to Board of DirectorsMeiraGTx Holdings plc (NASDAQ: MGTX), a vertically integrated, clinical stage genetic medicines company, today announced the appointment of Alan M. Sebulsky to its Board of Directors.
- Obesity Treatment Landscape 2026: Obesity Competitive Landscape and Clinical Trial Analysis 2026 Examines 200+ Companies and 200+ DrugsObesity drug development is shifting to oral, multi-agonist and ultra-long-acting therapies, creating opportunities in less frequent dosing, lean-mass preservation and novel mechanisms.
- Alzheimer's Disease Competitive Landscape and Clinical Trial Analysis Report 2026: More Than 200 Companies and 240 Therapies AssessedAlzheimer’s R&D is shifting toward disease modification, with amyloid, tau, RNA and immune targets driving trials, partnerships and oral therapy opportunities.
- White Biotech Market Poised for Growth Through 2031 as Demand Rises for Sustainable Manufacturing, Bio-Based Chemicals and Industrial EnzymesDemand for low-carbon biofuels, bioplastics, chemicals and enzymes is rising, fueled by policy and biotech advances. Asia-Pacific offers strong scaling opportunities.
- Innovent BiologicsInnovent to Present New Clinical Data of Next-gen IO and ADC Pipeline at the 2026 ESMO Annual MeetingInnovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for the treatment of oncology, cardiovascular and metabolic,...
- OSE Immunotherapeutics annonce la présentation des principaux résultats de l'étude de Phase 2 Combi-TED de Tedopi® dans le cancer du poumon non à petites cellules au Congrès 2026 de l’ESMONantes, France, 23 septembre 2026 – 7h30 CET – OSE Immunotherapeutics SA (ISIN : FR0012127173 ; Mnemo : OSE), une société de biotechnologie au stade clinique développant des thérapies first-in-class en immuno-oncologie et immuno-inflammation,annonce aujourd’hui que les principaux résultats de l’essai clinique international de Phase 2 Combi-TED de Tedopi® dans le cancer du poumon non à petites cellules, promu par FoRT, ont été sélectionnés pour une présentation orale au Congrès 2026 de l’European Society for Medical Oncology (ESMO) qui se tiendra à Madrid, Espagne, du 23 au 27 octobre 2026.
- Änderung im Verwaltungsrat von RocheCompanies: Roche HoldingDer Verwaltungsrat der Roche Holding AG hat beschlossen, Herrn Dr. Christophe Weber, ehemaliger CEO von Takeda Pharmaceuticals, der Generalversammlung am 9. März 2027 zur Neuwahl in den Verwaltungsrat vorzuschlagen.